Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.38 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 3/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bermoprofen SCHEMBL25434 | 0.89 | PTGS1 (0.49) | PTGS1ABCC4PTGS2OPRK1PDE4D | |
| SCHEMBL14434968 | 0.89 | PTGS1 (0.41) | PTGS1ABCC4PTGS2OPRK1PDE4D | |
| Bermoprofen SCHEMBL29454489 | 0.89 | PTGS1 (0.49) | PTGS1ABCC4PTGS2OPRK1PDE4D | |
| Bermoprofen SCHEMBL11441448 | 0.87 | PTGS1 (0.39) | PTGS1ABCC4PTGS2OPRK1PDE4D | |
| SCHEMBL13241522 | 0.85 | LMNA (0.37) | PTGS1ABCC4KDM4EMETAP1ATM | |
| SCHEMBL13220682 | 0.83 | KDM4E (0.35) | PTGS1ABCC4PTGS2OPRK1PDE4D | |
| SCHEMBL11576098 | 0.80 | KDM4E (0.45) | KDM4EMETAP1ATMRAD52HTT | |
| SCHEMBL13777304 | 0.80 | KDM4E (0.39) | PTGS1ABCC4PTGS2OPRK1PDE4D | |
| SCHEMBL11344285 | 0.79 | PTGS1 (0.33) | PTGS1ABCC4PTGS2OPRK1PDE4D | |
| SCHEMBL29481375 | 0.78 | LMNA (0.38) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802726-B2 | Use of nitrooxyderivative of drug for the treatment of muscular dystrophies | NICOX S.A. (FR) | 2014-08-12 | — | — | US | disclosed |
| US-8575222-B2 | Use of nitrooxyderivatives of drug for the treatment of muscular dystrophies | NICOX S.A. (FR) | 2013-11-05 | — | — | US | disclosed |
| US-20130137765-A1 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | NICOX S.A. (FR) | 2013-05-30 | — | — | US | disclosed |
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | NICOX SA (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | NICOX SA (FR) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | TNNC1, CPT1B, SMN1; SMN2 | PTGS1 292/4885ABCC4 2575/4885PTGS2 440/4885 |
| US-20130137765-A1 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | TNNC1, CPT1B, SMN1; SMN2 | PTGS1 248/4885ABCC4 2573/4885PTGS2 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.